SNTB2 Antibody (Mouse mAb) [A10J19] Datasheet

Biological Description

Specificity	SNTB2 Antibody (Mouse mAb) [A10J19] detects endogenous levels of total SNTB2 protein.
Background	SATB2 (special AT‑rich sequence‑binding protein 2) is a nuclear matrix–associated DNA‑binding protein in the SATB family that organizes higher‑order chromatin and coordinates transcriptional programs central to craniofacial, skeletal, and cortical development. SATB2 binds AT‑rich matrix attachment regions through its CUT domains and homeodomain, forming a chromatin “landing platform” that recruits chromatin remodelers and transcription factors, bringing distant cis‑regulatory elements into proximity and enabling synchronized control of large gene clusters involved in osteoblast differentiation, palate formation, and corticocortical projection neuron identity. In osteogenic lineages, SATB2 expression is enriched from branchial arch mesenchyme through committed osteoblasts, where it cooperates with RUNX2 and ATF4 on osteoblast‑specific promoters and enhancers, enhances expression of bone matrix genes such as Bglap and Col1a1, and suppresses inhibitors of osteogenesis, thereby shifting mesenchymal gene networks toward bone formation and supporting bone regeneration after injury. In the developing neocortex, SATB2 marks callosal projection neurons and regulates the balance between corticocortical and subcortical projection identities by modulating transcriptional programs that include axon guidance and synaptic genes; its chromatin‑level actions affect expression of factors controlling axon targeting across the corpus callosum and the assembly of cortical circuits required for higher cognitive functions. SATB2 expression is tissue‑ and stage‑specific and responds to extracellular signals, including BMP2/4/7, insulin, CNTF, and LIF, which act through their receptor pathways to adjust SATB2 transcription during key windows of skeletogenesis and neural development, integrating growth factor cues with chromatin architecture. Structural organization into matrix‑attachment binding domains and protein–protein interaction regions allows SATB2 to act both as a direct DNA‑bound regulator and as a scaffold linking other transcription factors to regulatory DNA, so that disruption of these domains alters chromatin topology and target gene output. Germline loss‑of‑function mutations or haploinsufficiency of SATB2 in humans cause a recognizable SATB2‑associated syndrome characterized by cleft or high‑arched palate, craniofacial anomalies, abnormal dentition, and intellectual disability, reflecting combined defects in craniofacial patterning, osteoblast maturation, and cortical circuit formation that mirror Satb2 perturbation phenotypes in animal models. Chromosomal rearrangements or point mutations leading to reduced SATB2 dosage cluster in individuals with these features, while normal alleles are retained in unaffected relatives, supporting a dosage‑sensitive role for SATB2 in human development and highlighting this chromatin organizer as a key node for researchers investigating gene networks that couple extracellular morphogen signaling, nuclear architecture, and lineage‑specific transcription in bone and brain.

Specificity

SNTB2 Antibody (Mouse mAb) [A10J19] detects endogenous levels of total SNTB2 protein.

Background

SATB2 (special AT‑rich sequence‑binding protein 2) is a nuclear matrix–associated DNA‑binding protein in the SATB family that organizes higher‑order chromatin and coordinates transcriptional programs central to craniofacial, skeletal, and cortical development. SATB2 binds AT‑rich matrix attachment regions through its CUT domains and homeodomain, forming a chromatin “landing platform” that recruits chromatin remodelers and transcription factors, bringing distant cis‑regulatory elements into proximity and enabling synchronized control of large gene clusters involved in osteoblast differentiation, palate formation, and corticocortical projection neuron identity. In osteogenic lineages, SATB2 expression is enriched from branchial arch mesenchyme through committed osteoblasts, where it cooperates with RUNX2 and ATF4 on osteoblast‑specific promoters and enhancers, enhances expression of bone matrix genes such as Bglap and Col1a1, and suppresses inhibitors of osteogenesis, thereby shifting mesenchymal gene networks toward bone formation and supporting bone regeneration after injury. In the developing neocortex, SATB2 marks callosal projection neurons and regulates the balance between corticocortical and subcortical projection identities by modulating transcriptional programs that include axon guidance and synaptic genes; its chromatin‑level actions affect expression of factors controlling axon targeting across the corpus callosum and the assembly of cortical circuits required for higher cognitive functions. SATB2 expression is tissue‑ and stage‑specific and responds to extracellular signals, including BMP2/4/7, insulin, CNTF, and LIF, which act through their receptor pathways to adjust SATB2 transcription during key windows of skeletogenesis and neural development, integrating growth factor cues with chromatin architecture. Structural organization into matrix‑attachment binding domains and protein–protein interaction regions allows SATB2 to act both as a direct DNA‑bound regulator and as a scaffold linking other transcription factors to regulatory DNA, so that disruption of these domains alters chromatin topology and target gene output. Germline loss‑of‑function mutations or haploinsufficiency of SATB2 in humans cause a recognizable SATB2‑associated syndrome characterized by cleft or high‑arched palate, craniofacial anomalies, abnormal dentition, and intellectual disability, reflecting combined defects in craniofacial patterning, osteoblast maturation, and cortical circuit formation that mirror Satb2 perturbation phenotypes in animal models. Chromosomal rearrangements or point mutations leading to reduced SATB2 dosage cluster in individuals with these features, while normal alleles are retained in unaffected relatives, supporting a dosage‑sensitive role for SATB2 in human development and highlighting this chromatin organizer as a key node for researchers investigating gene networks that couple extracellular morphogen signaling, nuclear architecture, and lineage‑specific transcription in bone and brain.

Usage Information

Application

WB, IP, IHC, IF, FCM

Dilution

WB	IP	IHC	IF
1:1000	1:1000	1:10-1:2000	1:50-1:500

Reactivity

Hamster, Human, Mouse, Non-human primate, Rat

Source

Mouse Monoclonal Antibody

MW

48 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/24411565/
https://pubmed.ncbi.nlm.nih.gov/35005110/

SNTB2 Antibody (Mouse mAb) [A10J19]

Biological Description

Usage Information

References

Application Data